Vertex Pharmaceuticals ( VRTX 3.06%) might be one of those special cases. Should you buy Vertex stock hand over fist before ...

J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...

You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have such strong ...

Orna Therapeutics, through its wholly owned subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with ...

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

One is from a phase 1/2 study evaluating VX-522, a messenger RNA therapy that could treat the roughly 5,000 CF patients who can't benefit from Vertex's other CF products. The other is from a phase ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell disease and transfusion-dependent beta thalassemia.

The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and ...